PT  - JOURNAL ARTICLE
AU  - Tsegaye, Tesfaye
AU  - Gebretekle, Gebremedhin Beedemariam
AU  - Ahmed, Mohammedjud Hassen
AU  - Bayissa, Tola
AU  - Habte, Bruck Messele
TI  - Asthma treatment outcome and factors associated with uncontrolled asthma among adult asthmatic patients in Addis Ababa, Ethiopia
AID  - 10.1101/2022.01.18.22269500
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.18.22269500
4099  - http://medrxiv.org/content/early/2022/01/24/2022.01.18.22269500.short
4100  - http://medrxiv.org/content/early/2022/01/24/2022.01.18.22269500.full
AB  - Background Asthma is a major public health challenge in the world resulting in significant health and economic burden. The modifiable and non-modifiable risk factors could have considerable impact on Asthma control and medical care. Our goal was to evaluate the treatment outcome and identify risk factors for poor asthma control among asthmatic patients in Addis Ababa, Ethiopia.Method A multicentre cross-sectional study using interview and chart review was conducted among asthmatic patients attending ambulatory care of two large public hospitals in Addis Ababa, Ethiopia between March and June 2018. The Global Initiative for Asthma Guideline was used to determine treatment outcomes. The variables of interest were described using descriptive statistics such as frequencies, percentages, mean, and standard deviations. Multivariable logistic regression was used to determine factors associated with uncontrolled asthma. All statistical significance level was determined at p<0.05.Result A total of 230 asthmatic patients were interviewed. More than half (65.2%) of patients were females and their mean age was 54±15.1 years. Overall, 50.4% of the patients had uncontrolled asthma status. More than two number of trigger factors (AOR=1.88; 95%CI:1.09-2.01), cold weather (AOR=2.11;95%CI: 1.51-2.42), exacerbations of asthma in the last 12 months (AOR=2.01;95%CI:1.39-2.32), moderate persistent asthma (AOR=3.47;95%CI:1.75-5.13), severe persistent asthma (AOR=2.90;95%CI:2.56-3.98) and Salbutamol Puff alone regimen (AOR=2.30;95%CI:2.01-2.76) use were significantly associated with uncontrolled asthma.Conclusion More than half of asthmatic patients had uncontrolled asthma treatment outcome. This indicates the need to give due attention to asthma patients with uncontrolled status particularly to those with identified risk factors. Health care providers should work in creating patient awareness on appropriate use of their prescribed medications, avoidance of asthma triggering factors for decreasing the progression of the disease and better asthma control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTT received funding from the Graduate Program of Addis Ababa University. The University however had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical Review Committee of the School of Pharmacy, Addis Ababa University (ERB/SOP/10/10/2018) and Saint Paul's Hospital Millennium Medical College (PM23/192)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableAll relevant data are within the manuscript and its Supporting Information filesGINAGlobal Initiative for Asthma GuidelineICSInhaled Corticosteroids